Time filter

Source Type

Bub C.B.,Hospital Israelita Albert Einstein | Torres M.A.,Lig Laboratorio Of Imunogenetica | Moraes M.E.,Lig Laboratorio Of Imunogenetica | Hamerschlak N.,Hospital Israelita Albert Einstein | Kutner J.M.,Hospital Israelita Albert Einstein
Revista Brasileira de Hematologia e Hemoterapia | Year: 2016

Background: Successful transfusion of platelet refractory patients is a challenge. Many potential donors are needed to sustain human leukocyte antigen matched-platelet transfusion programs because of the different types of antigens and the constant needs of these patients. For a highly mixed population such as the Brazilian population, the pool size required to provide adequate platelet support is unknown. Methods: A mathematical model was created to estimate the appropriate size of an unrelated donor pool to provide human leukocyte antigen-compatible platelet support for a Brazilian population. A group of 154 hematologic human leukocyte antigen-typed patients was used as the potential patient population and a database of 65,500 human leukocyte antigen-typed bone marrow registered donors was used as the donor population. Platelet compatibility was based on the grading system of Duquesnoy. Results: Using the mathematical model, a pool containing 31,940, 1710 and 321 donors would be necessary to match more than 80% of the patients with at least five completely compatible (no cross-reactive group), partial compatible (one cross-reactive group) or less compatible (two cross-reactive group) donors, respectively. Conclusion: The phenotypic diversity of the Brazilian population has probably made it more difficulty to find completely compatible donors. However, this heterogeneity seems to have facilitated finding donors when cross-reactive groups are accepted as proposed by the grading system of Duquesnoy. The results of this study may help to establish unrelated human leukocyte antigen-compatible platelet transfusions, a procedure not routinely performed in most Brazilian transfusion services. © 2015 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.

Loading Lig Laboratorio Of Imunogenetica collaborators
Loading Lig Laboratorio Of Imunogenetica collaborators